Executive Summary
HHS contracts from April 23, 2026 total $277,577,764 in obligations, with 1/3 defense-related primarily through DLA Troop Support's $65M award for DoD pharmaceuticals. The dominant agency theme is HHS/BARDA biodefense and pharmaceutical procurement, led by Emergent BioDefense Operations Lansing LLC's $211.4M firm-fixed-price award for smallpox antiviral R&D.
Highest-conviction signal is bullish on Emergent due to sole-source selection, $173.9M outlayed of $211.4M obligated, and potential $647.5M ceiling through 2032. Civilian HHS focus outweighs minor defense tie-in, but high pricing risk pervades all firm-fixed-price structures. Key watch item: Emergent options exercise and outlay progress beyond $173.9M toward 2028-10-01 current end.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from April 08, 2026.
Investment Signals (3)
- Emergent BioDefense Operations Lansing LLC Secures $211.4M BARDA Smallpox Antiviral R&D Award (HIGH)▲
Small business Emergent BioDefense Operations Lansing LLC received a non-competed $211,409,788 firm-fixed-price contract from HHS/BARDA, with $173,882,635 outlayed and options to $647,489,187 through potential 2032 end. Signals agency confidence in performer for biotech R&D (NAICS 541714).
- DLA Troop Support Awarded $65M HHS Contract for DoD Pharmaceuticals (LOW)▲
Government entity DLA Troop Support received $65M firm-fixed-price from HHS/NIH for pharmaceuticals (NAICS 325412), with $0 outlayed and 1-year performance starting 2026-04-10. No direct private sector investment implications.
- Pfizer Inc. Lands Minor $1.2M HHS BPA Call for Sterile Water (LOW)▲
Pfizer Inc. secured $1,167,976 firm-fixed-price BPA call from HHS/ASPR/ORM-SNS for sterile water (NAICS 325412), with $0 outlayed and 3-month performance ending 2025-05-16. Negligible relative to Pfizer scale.
Risk Flags (2)
- Execution [HIGH RISK]▼
High pricing risk on Emergent BioDefense Operations Lansing LLC's $211.4M firm-fixed-price contract due to biotech R&D uncertainties, despite $173.9M outlayed.
- Execution [MEDIUM RISK]▼
$0 outlayed to date on DLA Troop Support's $65M and Pfizer Inc.'s $1.2M HHS awards signals execution delays in future-dated pharma contracts.
Opportunities (2)
- ◆
Emergent BioDefense Operations Lansing LLC's non-competed BARDA award indicates sole-source confidence for smallpox antiviral R&D.
- ◆
Pfizer Inc. BPA call under HHS/ASPR framework could lead to repeat minor pharma awards.
Sector Themes (2)
- ◆
Emergent BioDefense Operations Lansing LLC's $211.4M non-competed award for smallpox antiviral (NAICS 541714) underscores BARDA's commitment to biotech R&D with large obligations and long-duration options.
- ◆
DLA Troop Support's $65M DoD pharma award and Pfizer Inc.'s $1.2M sterile water BPA call highlight HHS support for defense-related and SNS stockpiles (NAICS 325412).
Watch List (3)
- 👁
{"entity"=>"Emergent BioDefense Operations Lansing LLC", "reason"=>"$211.4M BARDA obligation with $173.9M outlayed and options to $647.5M", "trigger"=>"Options exercise; outlay progress; 2028-10-01 current end"}
- 👁
{"entity"=>"DLA Troop Support", "reason"=>"$65M HHS award for DoD pharma with $0 outlayed", "trigger"=>"Outlays from 2026-04-10; performance to 2027-04-09 end"}
- 👁
{"entity"=>"Pfizer Inc.", "reason"=>"$1.2M HHS BPA call with $0 outlayed", "trigger"=>"Performance completion by 2025-05-16; future BPA calls"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: HHS & Healthcare Contracts Intelligence
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals